Patent Exhaustion in Synthetic Biology

Patent exhaustion arises when an authorised sale of a patented product limits the patent holder’s ability to control the subsequent use or resale of that particular product. In synthetic biology, this doctrine becomes complex because products such as genetically engineered seeds, synthetic microorganisms, engineered enzymes and biological materials may reproduce, replicate or generate new biological products.

Indian patent law does not contain a single comprehensive provision codifying the exhaustion doctrine. Its application must be considered alongside patent infringement principles, licensing terms and the relevant statutory framework, including the Patents Act, 1970.

Important Case Laws

1. Bowman v. Monsanto Co., 569 U.S. 278 (2013)

The US Supreme Court held that buying patented genetically modified soybean seeds did not authorise a farmer to reproduce them through planting and harvesting without the patent holder’s permission. The initial authorised sale exhausted patent rights over the particular seeds sold, but did not authorise the creation of new generations of patented seeds. This is especially relevant to synthetic biology because biological products may self-replicate.

LII / Legal Information Institute

+1

2. Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017)

The US Supreme Court ruled that an authorised sale exhausts patent rights over the particular item sold, even where the seller attempts to impose post-sale restrictions. Such restrictions may sometimes be enforceable under contract law, but cannot preserve exhausted patent rights merely by being included in a sales agreement. In synthetic biology, this principle is relevant when engineered biological products are sold subject to restrictions on resale or reuse.

Justia U.S. Supreme Court Center

+1

3. Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008)

The US Supreme Court held that authorised sales of patented microprocessors exhausted relevant patent rights where the products substantially embodied the patented inventions. The judgment demonstrates that exhaustion may extend beyond the physical article expressly described in a patent when the sold component substantially embodies the patented technology. By analogy, it may be relevant where a sold biological component embodies a patented synthetic-biology process, although the result depends on the specific claims and facts.

Position under Indian Law

Section 48 of the Patents Act, 1970 grants patentees exclusive rights over making, using, offering for sale, selling and importing patented products, subject to the Act. Section 107A provides certain statutory exceptions, including specified acts connected with regulatory submissions. The precise scope of exhaustion in India may depend on judicial interpretation and the circumstances of the transaction.

The central distinction is between using or reselling the biological product already sold and making a new patented product through replication. An authorised sale may exhaust rights over the first product without automatically authorising reproduction. However, incidental biological replication and the terms of a particular licence may require careful factual and legal analysis.

Thus, patent exhaustion in synthetic biology seeks to balance the purchaser’s legitimate ownership rights with the patent holder’s rights over newly reproduced inventions. The Bowman, Impression Products and Quanta decisions offer important comparative guidance, but US judgments are persuasive rather than binding in Indian courts.